JP2019536430A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019536430A5 JP2019536430A5 JP2019514099A JP2019514099A JP2019536430A5 JP 2019536430 A5 JP2019536430 A5 JP 2019536430A5 JP 2019514099 A JP2019514099 A JP 2019514099A JP 2019514099 A JP2019514099 A JP 2019514099A JP 2019536430 A5 JP2019536430 A5 JP 2019536430A5
- Authority
- JP
- Japan
- Prior art keywords
- multispecific antibody
- heavy chain
- domain
- sequence
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims 20
- 102000004196 processed proteins & peptides Human genes 0.000 claims 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 14
- 201000010099 disease Diseases 0.000 claims 13
- 239000003814 drug Substances 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 6
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 6
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims 6
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 6
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 208000023275 Autoimmune disease Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 239000003153 chemical reaction reagent Substances 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 239000012636 effector Substances 0.000 claims 3
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims 2
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 239000000710 homodimer Substances 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022000116A JP7321303B2 (ja) | 2016-09-14 | 2022-01-04 | Ｃｄ３結合抗体 |
| JP2022000115A JP7431868B2 (ja) | 2016-09-14 | 2022-01-04 | Ｃｄ３結合抗体 |
| JP2023120345A JP2023156342A (ja) | 2016-09-14 | 2023-07-25 | Ｃｄ３結合抗体 |
| JP2023190748A JP7521728B2 (ja) | 2016-09-14 | 2023-11-08 | Ｃｄ３結合抗体 |
| JP2023190749A JP7521729B2 (ja) | 2016-09-14 | 2023-11-08 | Ｃｄ３結合抗体 |
| JP2024110717A JP2024153676A (ja) | 2016-09-14 | 2024-07-10 | Ｃｄ３結合抗体 |
| JP2025167195A JP2026021330A (ja) | 2016-09-14 | 2025-10-03 | Ｃｄ３結合抗体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662394360P | 2016-09-14 | 2016-09-14 | |
| US62/394,360 | 2016-09-14 | ||
| US201762491908P | 2017-04-28 | 2017-04-28 | |
| US62/491,908 | 2017-04-28 | ||
| PCT/US2017/038377 WO2018052503A1 (en) | 2016-09-14 | 2017-06-20 | Cd3 binding antibodies |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022000115A Division JP7431868B2 (ja) | 2016-09-14 | 2022-01-04 | Ｃｄ３結合抗体 |
| JP2022000116A Division JP7321303B2 (ja) | 2016-09-14 | 2022-01-04 | Ｃｄ３結合抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019536430A JP2019536430A (ja) | 2019-12-19 |
| JP2019536430A5 true JP2019536430A5 (enExample) | 2020-08-06 |
| JP7030109B2 JP7030109B2 (ja) | 2022-03-04 |
Family
ID=61619675
Family Applications (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019514099A Active JP7030109B2 (ja) | 2016-09-14 | 2017-06-20 | Ｃｄ３結合抗体 |
| JP2022000116A Active JP7321303B2 (ja) | 2016-09-14 | 2022-01-04 | Ｃｄ３結合抗体 |
| JP2022000115A Active JP7431868B2 (ja) | 2016-09-14 | 2022-01-04 | Ｃｄ３結合抗体 |
| JP2023120345A Pending JP2023156342A (ja) | 2016-09-14 | 2023-07-25 | Ｃｄ３結合抗体 |
| JP2023190749A Active JP7521729B2 (ja) | 2016-09-14 | 2023-11-08 | Ｃｄ３結合抗体 |
| JP2023190748A Active JP7521728B2 (ja) | 2016-09-14 | 2023-11-08 | Ｃｄ３結合抗体 |
| JP2024110717A Pending JP2024153676A (ja) | 2016-09-14 | 2024-07-10 | Ｃｄ３結合抗体 |
| JP2025167195A Pending JP2026021330A (ja) | 2016-09-14 | 2025-10-03 | Ｃｄ３結合抗体 |
Family Applications After (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022000116A Active JP7321303B2 (ja) | 2016-09-14 | 2022-01-04 | Ｃｄ３結合抗体 |
| JP2022000115A Active JP7431868B2 (ja) | 2016-09-14 | 2022-01-04 | Ｃｄ３結合抗体 |
| JP2023120345A Pending JP2023156342A (ja) | 2016-09-14 | 2023-07-25 | Ｃｄ３結合抗体 |
| JP2023190749A Active JP7521729B2 (ja) | 2016-09-14 | 2023-11-08 | Ｃｄ３結合抗体 |
| JP2023190748A Active JP7521728B2 (ja) | 2016-09-14 | 2023-11-08 | Ｃｄ３結合抗体 |
| JP2024110717A Pending JP2024153676A (ja) | 2016-09-14 | 2024-07-10 | Ｃｄ３結合抗体 |
| JP2025167195A Pending JP2026021330A (ja) | 2016-09-14 | 2025-10-03 | Ｃｄ３結合抗体 |
Country Status (32)
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017223111A1 (en) * | 2016-06-21 | 2017-12-28 | Teneobio, Inc. | Cd3 binding antibodies |
| AU2017316604C1 (en) | 2016-08-24 | 2025-01-30 | Teneobio, Inc. | Transgenic non-human animals producing modified heavy chain-only antibodies |
| HRP20240767T1 (hr) * | 2016-09-14 | 2024-09-13 | Teneoone, Inc. | Cd3 vezujuća antitijela |
| BR112019012354A2 (pt) | 2016-12-21 | 2019-11-26 | Teneobio, Inc. | anticorpos apenas de cadeia pesada anti-bcma |
| MX2019015563A (es) * | 2017-06-20 | 2020-07-28 | Teneoone Inc | Anticuerpos anti-bcma unicamente de cadena pesada. |
| CN110891971B (zh) | 2017-06-20 | 2024-01-12 | 特尼奥生物股份有限公司 | 仅有重链的抗bcma抗体 |
| CA3086665A1 (en) | 2017-12-22 | 2019-06-27 | Teneobio, Inc. | Heavy chain antibodies binding to cd22 |
| WO2019133761A1 (en) * | 2017-12-27 | 2019-07-04 | Teneobio, Inc. | Cd3-delta/epsilon heterodimer specific antibodies |
| MX420253B (es) | 2018-05-24 | 2025-02-10 | Janssen Biotech Inc | Anticuerpos anti-cd3 y usos de estos. |
| EA202190315A1 (ru) | 2018-07-19 | 2021-04-16 | Ридженерон Фармасьютикалз, Инк. | Химерные антигенные рецепторы со специфичностью к bcma и их применение |
| TWI838389B (zh) | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAｘ抗-CD3抗體及其用途 |
| SG11202011597RA (en) | 2018-07-20 | 2020-12-30 | Teneobio Inc | Heavy chain antibodies binding to cd19 |
| US10867104B2 (en) * | 2018-08-31 | 2020-12-15 | Taiwan Semiconductor Manufacturing Company Ltd. | Isolation circuit between power domains |
| MX2021004732A (es) | 2018-10-26 | 2021-06-04 | Teneobio Inc | Anticuerpos de cadena pesada que se unen a cd38. |
| AU2020252556B2 (en) * | 2019-04-05 | 2026-02-05 | Teneobio, Inc. | Heavy chain antibodies binding to PSMA |
| CR20210622A (es) * | 2019-06-14 | 2022-06-27 | Teneobio Inc | Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3 |
| MX2021015915A (es) * | 2019-06-21 | 2022-04-06 | Univ Degli Studi Magna Graecia Catanzaro | Anticuerpo monoclonal dirigido a un epítopo específico de cd43 asociado al cáncer. |
| JP2022542431A (ja) * | 2019-07-30 | 2022-10-03 | キューエルエスエフ バイオセラピューティクス， インコーポレイテッド | 二重特異性抗ｌｒｒｃ１５及びｃｄ３イプシロン抗体 |
| CN112574308A (zh) * | 2019-09-30 | 2021-03-30 | 和铂医药(苏州)有限公司 | 靶向bcma的抗体、双特异性抗体及其用途 |
| WO2021127489A1 (en) | 2019-12-18 | 2021-06-24 | Teneobio, Inc. | Heavy chain antibodies binding to cd38 |
| UY40898A (es) * | 2020-04-29 | 2024-10-15 | Teneobio Inc | Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas |
| AU2021263926A1 (en) | 2020-04-29 | 2023-01-19 | Teneoone, Inc. | Methods of treating multiple myeloma |
| MX2022013453A (es) | 2020-04-29 | 2022-11-16 | Teneobio Inc | Anticuerpos de cadena pesada multiespecificos con regiones constantes de cadena pesada modificadas. |
| IL298444A (en) | 2020-05-27 | 2023-01-01 | Janssen Biotech Inc | Proteins containing cd3 antigen binding sites and uses thereof |
| IL299027A (en) | 2020-06-30 | 2023-02-01 | Teneobio Inc | Multispecific antibodies that bind BCMA |
| EP4214233A1 (en) | 2020-09-16 | 2023-07-26 | Amgen Inc. | Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer |
| EP3991796A1 (en) * | 2020-10-27 | 2022-05-04 | Lindis Blood Care GmbH | An ex vivo method for removal of tumor cells from intra-operatively salvaged blood |
| TW202233684A (zh) | 2020-11-18 | 2022-09-01 | 美商泰尼歐生物公司 | 結合於葉酸受體α之重鏈抗體 |
| MX2023009874A (es) | 2021-02-25 | 2023-08-30 | Teneobio Inc | Anticuerpos anti-psma y estructuras car-t. |
| KR20230150825A (ko) | 2021-02-26 | 2023-10-31 | 테네오바이오, 인코포레이티드 | 항-muc1-c 항체 및 car-t 구조 |
| TW202304994A (zh) | 2021-04-02 | 2023-02-01 | 美商泰尼歐生物公司 | 促效性抗ｉｌ－２ｒ抗體及使用方法 |
| AU2022255709A1 (en) | 2021-04-06 | 2023-09-28 | Teneobio, Inc. | Anti-cd19 antibodies and car-t structures |
| CN117337303A (zh) | 2021-04-16 | 2024-01-02 | 特尼奥生物股份有限公司 | 抗cd20抗体及car-t结构 |
| WO2022271987A1 (en) | 2021-06-23 | 2022-12-29 | TeneoFour, Inc. | Anti-cd38 antibodies and epitopes of same |
| CN119569887A (zh) * | 2021-06-24 | 2025-03-07 | 益科思特(北京)医药科技发展有限公司 | 结合bcma和cd3的双特异性抗体及其制备方法与应用 |
| WO2023288191A1 (en) * | 2021-07-13 | 2023-01-19 | University Of Washington | Multiple de novo designed protein binding proteins |
| WO2023004197A1 (en) | 2021-07-23 | 2023-01-26 | Teneoten, Inc. | Heavy chain antibodies binding to hepatitis b surface antigen |
| MX2024001761A (es) | 2021-08-09 | 2024-04-29 | Harbour Biomed Shanghai Co Ltd | Anticuerpo dirigido contra cldn18.2, anticuerpo biespecífico y el uso de estos. |
| WO2023036326A1 (zh) * | 2021-09-13 | 2023-03-16 | 江苏先声药业有限公司 | 抗人cd3抗体及其应用 |
| IL312043A (en) | 2021-10-14 | 2024-06-01 | Teneobio Inc | Mesothelin binding proteins and their uses |
| JP2025524899A (ja) | 2022-07-27 | 2025-08-01 | テネオバイオ， インコーポレイテッド | メソテリン結合タンパク質及びその使用 |
| EP4598958A1 (en) | 2022-10-05 | 2025-08-13 | Amgen Inc. | Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof |
| WO2024178056A1 (en) | 2023-02-21 | 2024-08-29 | Teneobio, Inc. | C-kit binding proteins, chimeric antigen receptors, and uses thereof |
| WO2024191168A1 (ko) * | 2023-03-13 | 2024-09-19 | 머스트바이오 주식회사 | 신규한 cd3 결합항체 및 이를 포함한 다중특이 항체 |
| CN121666232A (zh) | 2023-05-31 | 2026-03-13 | 开普斯坦治疗公司 | 脂质纳米颗粒制剂和组合物 |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025217101A2 (en) | 2024-04-09 | 2025-10-16 | Amgen Inc. | Agonistic anti-il-2rbg heavy‑chain antibodies |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025222102A1 (en) * | 2024-04-19 | 2025-10-23 | TeneoTwo, Inc. | Therapeutic combinations of acalabrutinib and a multispecific antibody to treat b-cell malignancies |
| TW202544034A (zh) | 2024-05-06 | 2025-11-16 | 美商榮都醫療公司 | 結合至ｃｄ２８及ｎｅｃｔｉｎ－４之雙特異性抗體 |
| WO2025245399A1 (en) | 2024-05-23 | 2025-11-27 | Indapta Therapeutics, Inc. | Method of treating cancer with natural killer cells |
| GB2641580A (en) | 2024-06-07 | 2025-12-10 | T Therapeutics Ltd | Tumour-transforming multispecific proteins |
| WO2026006495A1 (en) | 2024-06-25 | 2026-01-02 | Alloy Therapeutics, Inc. | Anti-wt1/hla-a2 antibody and uses thereof |
| WO2026006492A2 (en) | 2024-06-25 | 2026-01-02 | Ypsilon Therapeutics, Inc. | Anti-prame/hla-a2 antibodies and uses thereof |
Family Cites Families (122)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6750325B1 (en) | 1989-12-21 | 2004-06-15 | Celltech R&D Limited | CD3 specific recombinant antibody |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5968509A (en) | 1990-10-05 | 1999-10-19 | Btp International Limited | Antibodies with binding affinity for the CD3 antigen |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| GB9206422D0 (en) | 1992-03-24 | 1992-05-06 | Bolt Sarah L | Antibody preparation |
| US7381803B1 (en) | 1992-03-27 | 2008-06-03 | Pdl Biopharma, Inc. | Humanized antibodies against CD3 |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6037453A (en) * | 1995-03-15 | 2000-03-14 | Genentech, Inc. | Immunoglobulin variants |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| AU728657B2 (en) | 1996-03-18 | 2001-01-18 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| DK0979281T3 (da) | 1997-05-02 | 2005-11-21 | Genentech Inc | Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele |
| SK288176B6 (sk) | 1999-01-07 | 2014-04-02 | Zymogenetics, Inc. | Farmaceutický prostriedok obsahujúci fúzny proteín, izolovaná molekula polynukleotidu, expresný vektor, kultivovaná bunka, spôsob prípravy polypeptidu a izolovaný polypeptid |
| KR20090016772A (ko) | 1999-08-17 | 2009-02-17 | 바이오겐 아이덱 엠에이 인코포레이티드 | Ｂａｆｆ 수용체(ｂｃｍａ), 면역조절제 |
| WO2001024812A1 (en) | 1999-10-06 | 2001-04-12 | N.V. Nutricia | USE OF TRANSFORMING GROWTH FACTOR β AND GROWTH FACTORS IN THE TREATMENT AND PREVENTION OF DISEASES OF THE INTESTINAL MUCOSA |
| UA74798C2 (uk) | 1999-10-06 | 2006-02-15 | Байоджен Айдек Ма Інк. | Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами |
| ES2637801T3 (es) | 2000-04-11 | 2017-10-17 | Genentech, Inc. | Anticuerpos multivalentes y usos de los mismos |
| EP1280826B1 (en) | 2000-05-12 | 2007-05-02 | Amgen Inc. | Polypeptides for inhibiting april-mediated b- and t-cell proliferation. |
| CA2433227A1 (en) * | 2000-12-29 | 2002-08-01 | Bio-Technology General, Inc. | Specific human antibodies for selective cancer therapy |
| WO2002066516A2 (en) | 2001-02-20 | 2002-08-29 | Zymogenetics, Inc. | Antibodies that bind both bcma and taci |
| CN1195779C (zh) | 2001-05-24 | 2005-04-06 | 中国科学院遗传与发育生物学研究所 | 抗人卵巢癌抗人cd3双特异性抗体 |
| GB0115256D0 (en) | 2001-06-21 | 2001-08-15 | Babraham Inst | Mouse light chain locus |
| AU2003287345A1 (en) | 2002-10-31 | 2004-06-07 | Genentech, Inc. | Methods and compositions for increasing antibody production |
| US7575893B2 (en) | 2003-01-23 | 2009-08-18 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
| WO2004106383A1 (en) | 2003-05-31 | 2004-12-09 | Micromet Ag | Pharmaceutical composition comprising a bispecific antibody for epcam |
| JP2008501621A (ja) | 2003-05-31 | 2008-01-24 | マイクロメット アクツィエン ゲゼルシャフト | Ｂ細胞関連疾患を処置するための二重特異性抗ｃｄ３、抗ｃｄ１９抗体構築物を含む薬学的組成物 |
| JP4948174B2 (ja) | 2003-10-16 | 2012-06-06 | マイクロメット アクツィエン ゲゼルシャフト | 多重特異的脱免疫ｃｄ３−結合物質 |
| KR101333449B1 (ko) * | 2003-12-10 | 2013-11-26 | 메다렉스, 엘.엘.시. | Ｉｐ―１０ 항체 및 그의 용도 |
| US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
| CA2569509C (en) | 2004-06-03 | 2014-08-12 | Novimmune S.A. | Anti-cd3 antibodies and methods of use thereof |
| EP4353819A3 (en) | 2004-07-22 | 2024-07-17 | Erasmus University Medical Center Rotterdam | Binding molecules |
| BRPI0607203A2 (pt) | 2005-02-18 | 2009-08-25 | Medarex Inc | anticorpo anti-cd30 isolado, célula hospedeira, métodos para inibir o crescimento de células cd30+, e, uso de um anticorpo anti-cd30 desfucosilado |
| US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
| ES2776657T3 (es) | 2005-06-14 | 2020-07-31 | Amgen Inc | Formulaciones de proteínas autotamponantes |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| EA014025B1 (ru) | 2005-09-12 | 2010-08-30 | Новиммун С.А. | Композиции антитела против cd3 |
| EP1940881B1 (en) | 2005-10-11 | 2016-11-30 | Amgen Research (Munich) GmbH | Compositions comprising cross-species-specific antibodies and uses thereof |
| JP2009511032A (ja) * | 2005-10-11 | 2009-03-19 | アブリンクス エン．ヴェー． | Ｅｇｆｒおよびｉｇｆ−ｉｒに対するナノボディおよびポリペプチド |
| WO2007055916A2 (en) | 2005-11-07 | 2007-05-18 | The Rockefeller University | Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof |
| AU2006318539B2 (en) | 2005-11-23 | 2012-09-13 | Genentech, Inc. | Methods and compositions related to B cell assays |
| CN101426815A (zh) | 2005-12-06 | 2009-05-06 | 杜门蒂斯有限公司 | 具有表皮生长因子受体和/或血管内皮生长因子结合特异性的配体及其使用方法 |
| NZ572379A (en) | 2006-04-05 | 2012-06-29 | Univ Rockefeller | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
| WO2007117600A2 (en) | 2006-04-07 | 2007-10-18 | Macrogenics, Inc. | Combination therapy for treating autoimmune diseases |
| US7862813B2 (en) | 2006-07-29 | 2011-01-04 | Bjork Jr Robert Lamar | Bi-specific monoclonal antibody (specific for both CD3 and CD11b) therapeutic drug |
| EA200970250A1 (ru) * | 2006-09-05 | 2010-02-26 | Медарекс, Инк. | Антитела к костным морфогенетическим белкам и их рецепторам и способы их применения |
| RU2769948C2 (ru) | 2007-04-03 | 2022-04-11 | Эмджен Рисерч (Мьюник) Гмбх | CD3-Эпсилон-связывающий домен с межвидовой специфичностью |
| AU2008234019B2 (en) | 2007-04-03 | 2014-05-29 | Amgen Research (Munich) Gmbh | Cross-species-specific bispecific binders |
| WO2008119567A2 (en) | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific cd3-epsilon binding domain |
| KR102096731B1 (ko) | 2007-06-01 | 2020-04-02 | 오픈 모노클로날 테크놀로지, 인코포레이티드 | 내생적 면역글로불린 유전자를 억제하고 트랜스제닉 인간 이디오타입 항체를 생산하기 위한 방법 및 조성물 |
| JP5739326B2 (ja) | 2008-04-25 | 2015-06-24 | ザイモジェネティクス， インコーポレイテッド | Ｂ細胞上でのｂｃｍａタンパク発現レベル及び診断法における使用 |
| US20100122358A1 (en) | 2008-06-06 | 2010-05-13 | Crescendo Biologics Limited | H-Chain-only antibodies |
| EP3106468A1 (en) | 2008-10-01 | 2016-12-21 | Amgen Research (Munich) GmbH | Cross-species-specific psmaxcd3 bispecific single chain antibody |
| AU2009299794B2 (en) | 2008-10-01 | 2015-08-13 | Amgen Research (Munich) Gmbh | Cross-species-specific single domain bispecific single chain antibody |
| AU2009299793B2 (en) | 2008-10-01 | 2016-03-10 | Amgen Research (Munich) Gmbh | Bispecific single chain antibodies with specificity for high molecular weight target antigens |
| RU2547600C2 (ru) | 2008-10-01 | 2015-04-10 | Эмджен Рисерч (Мьюник) Гмбх | Pscaxcd3, cd19xcd3, c-metxcd3, эндосиалинxcd3, epcamxcd3, igf-1rxcd3 или fap-альфаxcd3 биспецифическое одноцепочечное антитело с межвидовой специфичностью |
| AU2010224160A1 (en) | 2009-03-10 | 2011-09-22 | Biogen Idec Ma Inc. | Anti-BCMA antibodies |
| GB0905023D0 (en) | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| US10143186B2 (en) * | 2010-02-08 | 2018-12-04 | Regeneron Pharmaceuticals, Inc. | Common light chain mouse |
| TWI653333B (zh) | 2010-04-01 | 2019-03-11 | 安進研究（慕尼黑）有限責任公司 | 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體 |
| EP2640750A1 (en) | 2010-11-16 | 2013-09-25 | Boehringer Ingelheim International GmbH | Agents and methods for treating diseases that correlate with bcma expression |
| WO2012122512A1 (en) | 2011-03-10 | 2012-09-13 | Hco Antibody, Inc. | Recombinant production of mixtures of single chain antibodies |
| CN103619876A (zh) | 2011-03-10 | 2014-03-05 | Hco抗体股份有限公司 | 双特异性三链抗体样分子 |
| US20130101599A1 (en) | 2011-04-21 | 2013-04-25 | Boehringer Ingelheim International Gmbh | Bcma-based stratification and therapy for multiple myeloma patients |
| SG194176A1 (en) | 2011-05-27 | 2013-12-30 | Glaxo Group Ltd | Bcma (cd269/tnfrsf17) -binding proteins |
| TWI679212B (zh) * | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| US10202452B2 (en) | 2012-04-20 | 2019-02-12 | Aptevo Research And Development Llc | CD3 binding polypeptides |
| BR112014032916A2 (pt) * | 2012-06-28 | 2017-08-01 | Pfizer | anticorpos anti-fármacos e usos destes para o monitoramento de fármaco |
| US20150203591A1 (en) * | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| US10002206B2 (en) | 2012-10-26 | 2018-06-19 | Saturn Licensing Llc | Information processing device and information processing method |
| EP2914628A1 (en) | 2012-11-01 | 2015-09-09 | Max-Delbrück-Centrum für Molekulare Medizin | An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases |
| TW201425336A (zh) | 2012-12-07 | 2014-07-01 | Amgen Inc | Ｂｃｍａ抗原結合蛋白質 |
| EP4269602A3 (en) * | 2012-12-14 | 2023-12-27 | OmniAB, Inc. | Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same |
| ES2667420T3 (es) * | 2013-02-05 | 2018-05-10 | Engmab Sàrl | Anticuerpos biespecíficos contra cd3epsilon y bcma |
| EP2762496A1 (en) * | 2013-02-05 | 2014-08-06 | EngMab AG | Method for the selection of antibodies against BCMA |
| US20150118251A1 (en) | 2013-10-31 | 2015-04-30 | Sanofi | Specific anti-cd38 antibodies for treating human cancers |
| EP3066133A1 (en) | 2013-11-04 | 2016-09-14 | Glenmark Pharmaceuticals S.A. | Production of t cell retargeting hetero-dimeric immunoglobulins |
| WO2015095412A1 (en) * | 2013-12-19 | 2015-06-25 | Zhong Wang | Bispecific antibody with two single-domain antigen-binding fragments |
| DK3105252T3 (da) | 2014-02-12 | 2019-10-14 | Michael Uhlin | Bispecifikke antistoffer til anvendelse ved stamcelletransplantation |
| TWI701042B (zh) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| KR102497443B1 (ko) | 2014-03-28 | 2023-02-08 | 젠코어 인코포레이티드 | Cd38 및 cd3에 결합하는 이중특이적 항체 |
| US10174095B2 (en) | 2014-07-21 | 2019-01-08 | Novartis Ag | Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor |
| AU2015292406B2 (en) * | 2014-07-25 | 2021-03-11 | Cytomx Therapeutics, Inc | Anti-CD3 antibodies, activatable anti-CD3 antibodies, multispecific anti-CD3 antibodies, multispecific activatable anti-CD3 antibodies, and methods of using the same |
| US11547099B2 (en) | 2014-10-22 | 2023-01-10 | Crescendo Biologies Limited | Transgenic mice |
| EP3023437A1 (en) * | 2014-11-20 | 2016-05-25 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| BR112017010513A2 (pt) * | 2014-11-20 | 2018-04-03 | F. Hoffmann-La Roche Ag | ?cadeias leves comuns e métodos de uso? |
| SMT201900596T1 (it) | 2014-12-12 | 2019-11-13 | Bluebird Bio Inc | Recettori chimerici di antigene per bcma |
| CN105777906B (zh) * | 2014-12-19 | 2019-04-23 | 苏州丁孚靶点生物技术有限公司 | 抗pd-l1全人抗体及其应用 |
| GB201500461D0 (en) | 2015-01-12 | 2015-02-25 | Cresendo Biolog Ltd | Therapeutic molecules |
| EP3056512A1 (en) * | 2015-02-10 | 2016-08-17 | Medizinische Universität Wien | Antibody construct |
| CN106211261B (zh) | 2015-04-10 | 2020-10-16 | 中兴通讯股份有限公司 | 信息处理方法及通信节点 |
| BR112017024877A2 (pt) | 2015-05-20 | 2019-09-17 | Janssen Biotech, Inc. | anticorpo anti-cd38 e seu uso no tratamento de amiloidose de cadeia leve e outras malignidades hematológicas positivas para cd38 |
| CN105384825B (zh) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| TWI811023B (zh) | 2015-08-17 | 2023-08-01 | 美商健生生物科技公司 | 抗bcma抗體，結合bcma及cd3之雙特異性抗原結合分子及其用途 |
| WO2017081211A2 (en) | 2015-11-10 | 2017-05-18 | University Medical Center Hamburg - Eppendorf | Antigen-binding polypeptides directed against cd38 |
| WO2017223111A1 (en) | 2016-06-21 | 2017-12-28 | Teneobio, Inc. | Cd3 binding antibodies |
| AU2017316604C1 (en) | 2016-08-24 | 2025-01-30 | Teneobio, Inc. | Transgenic non-human animals producing modified heavy chain-only antibodies |
| HRP20240767T1 (hr) * | 2016-09-14 | 2024-09-13 | Teneoone, Inc. | Cd3 vezujuća antitijela |
| BR112019012354A2 (pt) | 2016-12-21 | 2019-11-26 | Teneobio, Inc. | anticorpos apenas de cadeia pesada anti-bcma |
| MX2019015563A (es) | 2017-06-20 | 2020-07-28 | Teneoone Inc | Anticuerpos anti-bcma unicamente de cadena pesada. |
| CN110891971B (zh) | 2017-06-20 | 2024-01-12 | 特尼奥生物股份有限公司 | 仅有重链的抗bcma抗体 |
| WO2019000223A1 (en) | 2017-06-27 | 2019-01-03 | Nanjing Legend Biotech Co., Ltd. | ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF |
| KR20250012203A (ko) | 2017-06-30 | 2025-01-23 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | 인간 도메인을 갖는 항-b 세포 성숙화 항원 키메라성 항원 수용체 |
| CA3086665A1 (en) | 2017-12-22 | 2019-06-27 | Teneobio, Inc. | Heavy chain antibodies binding to cd22 |
| WO2019133761A1 (en) * | 2017-12-27 | 2019-07-04 | Teneobio, Inc. | Cd3-delta/epsilon heterodimer specific antibodies |
| KR20210013184A (ko) * | 2018-05-24 | 2021-02-03 | 아얄라 파마큐티컬즈 아이엔씨. | 비스플루오로알킬-1,4-벤조디아제피논 화합물과 면역요법제를 포함하는 조성물 및 이의 사용 방법 |
| SG11202011597RA (en) | 2018-07-20 | 2020-12-30 | Teneobio Inc | Heavy chain antibodies binding to cd19 |
| BR112021004680A2 (pt) | 2018-09-21 | 2021-08-31 | Teneobio, Inc. | Métodos para purificar anticorpos multiespecíficos heterodiméricos |
| MX2021004732A (es) | 2018-10-26 | 2021-06-04 | Teneobio Inc | Anticuerpos de cadena pesada que se unen a cd38. |
| AU2020252556B2 (en) | 2019-04-05 | 2026-02-05 | Teneobio, Inc. | Heavy chain antibodies binding to PSMA |
| CR20210622A (es) * | 2019-06-14 | 2022-06-27 | Teneobio Inc | Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3 |
| MX2022013453A (es) | 2020-04-29 | 2022-11-16 | Teneobio Inc | Anticuerpos de cadena pesada multiespecificos con regiones constantes de cadena pesada modificadas. |
| AU2021263926A1 (en) | 2020-04-29 | 2023-01-19 | Teneoone, Inc. | Methods of treating multiple myeloma |
| UY40898A (es) | 2020-04-29 | 2024-10-15 | Teneobio Inc | Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas |
| US20220235380A1 (en) * | 2021-01-26 | 2022-07-28 | Arsenal Biosciences, Inc. | Immune cells having co-expressed shrnas and logic gate systems |
| IL312043A (en) * | 2021-10-14 | 2024-06-01 | Teneobio Inc | Mesothelin binding proteins and their uses |
-
2017
- 2017-06-20 HR HRP20240767TT patent/HRP20240767T1/hr unknown
- 2017-06-20 DK DK22159278.5T patent/DK4050034T3/da active
- 2017-06-20 PT PT221592785T patent/PT4050034T/pt unknown
- 2017-06-20 BR BR112019004873-1A patent/BR112019004873A2/pt unknown
- 2017-06-20 PE PE2024000894A patent/PE20241349A1/es unknown
- 2017-06-20 EP EP17851217.4A patent/EP3512549A4/en active Pending
- 2017-06-20 IL IL313895A patent/IL313895A/en unknown
- 2017-06-20 CR CR20190198A patent/CR20190198A/es unknown
- 2017-06-20 CA CA3036550A patent/CA3036550A1/en active Pending
- 2017-06-20 WO PCT/US2017/038377 patent/WO2018052503A1/en not_active Ceased
- 2017-06-20 EP EP24172651.2A patent/EP4417263A3/en active Pending
- 2017-06-20 MX MX2019002967A patent/MX2019002967A/es unknown
- 2017-06-20 LT LTEP22159278.5T patent/LT4050034T/lt unknown
- 2017-06-20 JP JP2019514099A patent/JP7030109B2/ja active Active
- 2017-06-20 IL IL265321A patent/IL265321B2/en unknown
- 2017-06-20 AU AU2017327723A patent/AU2017327723B2/en active Active
- 2017-06-20 CN CN202311092843.4A patent/CN117603353A/zh active Pending
- 2017-06-20 PE PE2019000520A patent/PE20190976A1/es unknown
- 2017-06-20 KR KR1020197010099A patent/KR102505681B1/ko active Active
- 2017-06-20 KR KR1020227006672A patent/KR102507537B1/ko active Active
- 2017-06-20 BR BR122022002481A patent/BR122022002481A8/pt unknown
- 2017-06-20 RS RS20240647A patent/RS65595B1/sr unknown
- 2017-06-20 CN CN201780062822.4A patent/CN109843325B/zh active Active
- 2017-06-20 KR KR1020237007421A patent/KR20230035706A/ko not_active Ceased
- 2017-06-20 ES ES22159278T patent/ES2980623T3/es active Active
- 2017-06-20 KR KR1020247009294A patent/KR20240044520A/ko not_active Ceased
- 2017-06-20 IL IL290517A patent/IL290517B2/en unknown
- 2017-06-20 EP EP22159278.5A patent/EP4050034B1/en active Active
- 2017-06-20 US US16/332,665 patent/US11505606B2/en active Active
- 2017-06-20 MY MYPI2022002552A patent/MY200988A/en unknown
- 2017-06-20 PL PL22159278.5T patent/PL4050034T3/pl unknown
- 2017-06-20 CN CN202210150122.3A patent/CN114395048B/zh active Active
- 2017-06-20 CR CR20220578A patent/CR20220578A/es unknown
- 2017-06-20 SI SI201731524T patent/SI4050034T1/sl unknown
- 2017-06-20 CR CR20220408A patent/CR20220408A/es unknown
- 2017-06-20 UA UAA201903677A patent/UA126384C2/uk unknown
- 2017-06-20 HU HUE22159278A patent/HUE066651T2/hu unknown
- 2017-06-20 KR KR1020257018726A patent/KR20250088655A/ko active Pending
- 2017-06-20 FI FIEP22159278.5T patent/FI4050034T3/fi active
-
2019
- 2019-03-13 MX MX2024011615A patent/MX2024011615A/es unknown
- 2019-03-13 PH PH12019500545A patent/PH12019500545A1/en unknown
- 2019-03-13 MX MX2024011616A patent/MX2024011616A/es unknown
- 2019-03-13 DO DO2019000059A patent/DOP2019000059A/es unknown
- 2019-03-13 MX MX2022002018A patent/MX2022002018A/es unknown
- 2019-03-13 SA SA523442262A patent/SA523442262B1/ar unknown
- 2019-03-13 SA SA522431672A patent/SA522431672B1/ar unknown
- 2019-03-13 CL CL2019000643A patent/CL2019000643A1/es unknown
- 2019-04-12 EC ECSENADI201926304A patent/ECSP19026304A/es unknown
- 2019-04-12 CO CONC2019/0003706A patent/CO2019003706A2/es unknown
-
2021
- 2021-10-01 US US17/492,444 patent/US11421027B2/en active Active
- 2021-12-09 CL CL2021003290A patent/CL2021003290A1/es unknown
- 2021-12-09 CL CL2021003289A patent/CL2021003289A1/es unknown
-
2022
- 2022-01-04 JP JP2022000116A patent/JP7321303B2/ja active Active
- 2022-01-04 JP JP2022000115A patent/JP7431868B2/ja active Active
- 2022-02-24 AU AU2022201278A patent/AU2022201278B2/en active Active
- 2022-03-18 ZA ZA2022/03250A patent/ZA202203250B/en unknown
- 2022-08-19 US US17/821,143 patent/US20230082151A1/en not_active Abandoned
- 2022-10-03 US US17/937,750 patent/US20230272075A1/en not_active Abandoned
- 2022-10-27 DO DO2022000233A patent/DOP2022000233A/es unknown
- 2022-12-26 CL CL2022003769A patent/CL2022003769A1/es unknown
-
2023
- 2023-07-25 JP JP2023120345A patent/JP2023156342A/ja active Pending
- 2023-08-24 DO DO2023000165A patent/DOP2023000165A/es unknown
- 2023-11-08 JP JP2023190749A patent/JP7521729B2/ja active Active
- 2023-11-08 JP JP2023190748A patent/JP7521728B2/ja active Active
-
2024
- 2024-07-10 JP JP2024110717A patent/JP2024153676A/ja active Pending
-
2025
- 2025-03-24 US US19/088,689 patent/US20250340638A1/en active Pending
- 2025-10-03 JP JP2025167195A patent/JP2026021330A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019536430A5 (enExample) | ||
| JP2022061993A5 (enExample) | ||
| JP2020103301A5 (enExample) | ||
| IL299221A (en) | Cd3 binding antibodies | |
| JP2020501531A5 (enExample) | ||
| JP2020521448A5 (enExample) | ||
| EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
| JP2018502050A5 (enExample) | ||
| JP2019501883A5 (enExample) | ||
| RU2018139811A (ru) | Мультиспецифические антигенсвязывающие конструкции, нацеливающие иммунотерапевтические средства | |
| JP2019524693A5 (enExample) | ||
| JP2019513777A5 (enExample) | ||
| JP2018527919A5 (enExample) | ||
| JP2017535257A5 (enExample) | ||
| CN117285642A (zh) | 制导和导航控制蛋白及其制备和使用方法 | |
| JP2017506067A5 (enExample) | ||
| CN114206931B (zh) | 抗pd-1抗体及其用途 | |
| JP2019503363A (ja) | 急性リンパ芽球性白血病を治療するための二重特異性の抗ｃｄ２０／抗ｃｄ３抗体 | |
| JP2020522474A5 (enExample) | ||
| JP2013502913A5 (enExample) | ||
| JPWO2019175223A5 (enExample) | ||
| JP2013527761A5 (enExample) | ||
| JP2020522473A5 (enExample) | ||
| WO2023174396A1 (zh) | 一种新型免疫调节剂的开发和应用 | |
| JP2020530777A (ja) | 多重特異性抗体とその作製及び使用方法 |